| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 National Food Biotechnology Centre and Teagasc, Dairy Products Research Centre, Republic of Ireland
2 Teagasc, Dairy Products Research Centre and Microbiology Department, University College Cork
3 Dairy Production Centre, Moorepark, Fermoy, Co. Cork, Republic of Ireland
4 National Food Biotechnology Centre and Microbiology Department, University College Cork
5 Teagasc, Dairy Products Research Centre, Republic of Ireland
We assessed the effectiveness of a novel dry cow treatment containing lacticin 3147 using deliberate challenge studies in lactating cows. Infection-free quarters of lactating cows were infused with Teat seal (Cross Vetpharm Group, Ltd., Dublin, Ireland) combined with the food-grade bacteriocin, lacticin 3147. Natural infection of the teat was simulated by deliberately introducing Staphylococcus aureus into the teat duct and teat sinus. Relative to control quarters, teat seal plus lacticin 3147 reduced the number of teats shedding viable cells when an inoculum of either 
1.7 x 103 or 6.8 x 103 cfu per teat was used. In addition, the numbers of challenge organisms in those teats from which S. aureus was subsequently recovered were also reduced. However, when the concentration of bacteriocin in the teat seal formulation was reduced by approximately 50%, the number of teats shedding S. aureus cells was not reduced. These data indicate the potential for lacticin 3147 to prevent staphylococcal mastitis infections when a sufficient concentration of the bacteriocin is present. This study also highlights the application of a lactating-cow model to assess the effectiveness of antimicrobial intramammary products on mastitic cell populations.
Key Words: mastitis • nonantibiotic treatment • bacteriocin • Staphylococcus aureus
Submitted on July 19, 2000
Accepted on February 21, 2000
This article has been cited by other articles:
|
|
 |
|
  M. J. Raymond, R. D. Wohrle, and D. R. Call Assessment and promotion of judicious antibiotic use on dairy farms in Washington State. J Dairy Sci, August 1, 2006; 89(8): 3228 - 3240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Morgan, P. M. O'Connor, P. D. Cotter, R. P. Ross, and C. Hill Sequential Actions of the Two Component Peptides of the Lantibiotic Lacticin 3147 Explain Its Antimicrobial Activity at Nanomolar Concentrations Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2606 - 2611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. O'Flaherty, R. P. Ross, W. Meaney, G. F. Fitzgerald, M. F. Elbreki, and A. Coffey Potential of the Polyvalent Anti-Staphylococcus Bacteriophage K for Control of Antibiotic-Resistant Staphylococci from Hospitals Appl. Envir. Microbiol., April 1, 2005; 71(4): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. O'Sullivan, M. P. Ryan, R. P. Ross, and C. Hill Generation of Food-Grade Lactococcal Starters Which Produce the Lantibiotics Lacticin 3147 and Lacticin 481 Appl. Envir. Microbiol., June 1, 2003; 69(6): 3681 - 3685. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
